| SC 13G/A | 2017-02-14 | FMR LLC | Tobira Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-01-18 | MONTREUX EQUITY PARTNERS IV LP | Tobira Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-11-04 | Domain Partners VI, L.P. | Tobira Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-11-03 | Frazier Healthcare V, LP | Tobira Therapeutics, Inc. | - | - | EDGAR |
| SC 13D/A | 2016-11-02 | Allergan plc | Tobira Therapeutics, Inc. | 1,000 | 100.0% | EDGAR |
| SC 13D | 2016-09-29 | Allergan plc | Tobira Therapeutics, Inc. | 6,838,661 | 36.3% | EDGAR |
| SC 13G | 2016-09-23 | STONEPINE CAPITAL, L.P. | Tobira Therapeutics, Inc. | 800,000 | 4.3% | EDGAR |
| SC 13G/A | 2016-09-22 | BIOTECHNOLOGY VALUE FUND L P | Tobira Therapeutics, Inc. | 173,932 | 2.1% | EDGAR |
| SC 13G | 2016-09-22 | Pentwater Capital Management LP | Tobira Therapeutics, Inc. | 3,533,200 | 18.8% | EDGAR |
| SC 13G/A | 2016-09-01 | BIOTECHNOLOGY VALUE FUND L P | Tobira Therapeutics, Inc. | 981,393 | 5.2% | EDGAR |
| SC 13G/A | 2016-08-10 | Novo A/S | Tobira Therapeutics, Inc. | 173,905 | 0.9% | EDGAR |
| SC 13G/A | 2016-02-16 | BIOTECHNOLOGY VALUE FUND L P | Tobira Therapeutics, Inc. | 536,757 | 2.9% | EDGAR |
| SC 13G/A | 2016-02-16 | MONTREUX EQUITY PARTNERS IV LP | Tobira Therapeutics, Inc. | 929,573 | 4.9% | EDGAR |
| SC 13G/A | 2016-02-12 | STONEPINE CAPITAL, L.P. | Tobira Therapeutics, Inc. | 833,377 | 4.4% | EDGAR |
| SC 13G/A | 2016-02-12 | QUAKER BIO VENTURES LP | Tobira Therapeutics, Inc. | 82,463 | - | EDGAR |
| SC 13G/A | 2016-02-12 | Novo A/S | Tobira Therapeutics, Inc. | 2,471,405 | 13.1% | EDGAR |
| SC 13G | 2016-02-12 | FMR LLC | Tobira Therapeutics, Inc. | 1,540,248 | 8.8% | EDGAR |
| SC 13D/A | 2015-05-20 | Domain Partners VI, L.P. | Tobira Therapeutics, Inc. | 285,679 | 1.6% | EDGAR |
| SC 13D | 2015-05-18 | Frazier Healthcare V, LP | Tobira Therapeutics, Inc. | 2,668,570 | 15.3% | EDGAR |
| SC 13G | 2015-05-18 | Montreux Equity Partners IV, L.P. | Tobira Therapeutics, Inc. | 1,535,758 | 8.8% | EDGAR |